Skip to content

Coronary Flow Reserve Evaluation in PET and in MRI Scanner in Heart Transplanted Patients : Comparison With Multi-detectors Scanner

Coronary Flow Reserve Evaluation in PET and in MRI Scanner in Heart Transplanted Patients : Comparison With Multi-detectors Scanner

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01231815
Acronym
RECOPE
Enrollment
30
Registered
2010-11-01
Start date
2010-11-30
Completion date
2014-12-31
Last updated
2014-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Disease

Keywords

Heart transplantation

Brief summary

Heart transplantation is the ultimate therapeutic option in patients with end-stage heart failure. Since advances in the treatment of acute rejection has increased early transplant survival, cardiac allograft vasculopathy (CAV) is the main factor limiting long-term survival. The prevalence of angiographically proven CAV is high, documented in 40-50% of transplant recipients 5 years after transplantation. Therefore, annual coronary angiography remains widely used to monitor transplanted patients, although pathologic studies and intravascular ultrasonography have demonstrated that coronary angiography underestimates the severity of CAV. Perfusion SPECT may underestimate allograft vasculopathy in case of diffuse coronary lesions. In this setting, the assessment of coronary reserve by means of Positron Emission Tomography (PET) and perfusion cardiac magnetic resonance imaging (CMR) have not been investigated.

Detailed description

Aim of the study. The aim of the study is to compare the quantitative (using 15O-H2O PET) and semi-quantitative (using perfusion CMR) assessment of coronary reserve to the presence of coronary artery lesions documented by multidetector CT coronary angiography. Methods. 30 patients with heart transplantation \> 3 yrs will be included in two heart transplantation centers (Caen and Rouen university hospitals) Expected results. * To demonstrate that quantitative analysis of coronary reserve using 15O-H2O PET allows the assessment of cardiac allograft vasculopathy * To establish the feasibility of adenosine stress CMR in this population * To show a relationship between coronary lesions demonstrated using MDCT and the extent of coronary reserve impairment assessed using cardiac functional imaging (PET and CMR).

Interventions

RADIATION15O-H2O PET -

Assessment of coronary reserve using PET

RADIATIONMRI

Assessment of coronary reserve using MRI

Sponsors

University Hospital, Caen
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient with heart transplantation \> 3 years * Candidate to a routine coronary angiography * Age \> 18 years old * signed informed consent

Exclusion criteria

* Pregnancy or breast feeding women * Recent acute coronary syndrome (\<4weeks) * High Blood Pressure ((SBP \>=180 mmHg or DBP \>=110 mmHg) * Significant ventricular or supraventricular arrythmia * Atrioventricular 2nd or 3rd degree blocks, long QT syndrome * Standard contraindications to MRI including pacemaker/defibrillator, metallic clips on brain aneurysms, metal fragment in the eye etc... * Congestive heart failure * Hemodynamic instability * Intolerance or contraindication to adenosine (history of asthma or bronchoplastic disease). * Severe and known pulmonary artery hypertension * Severe hypotension \< 90 mmHg * Contraindication to contrast iodinated media (allergy, patients with chronic renal failure with creatinine clearance \< 50 ml/min, multiple myeloma, hyperthyroidism,...)

Design outcomes

Primary

MeasureTime frame
To compare the coronary flow reserve by a quantitative method (PET ...6 months

Countries

France

Contacts

Primary ContactAlain MANRIQUE, MD
manrique@cyceron.fr+33 2 31 47 02 87
Backup ContactDenis AGOSTINI, PhD
agostini-d@chu-caen.fr+33 2 31 06 32 46

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026